Izoniazida Atb (Isoniazid)

Isoniazid is activated by the bacterial enzyme KatG and then inhibits the synthesis of mycolic acids, which are vital components of the mycobacterial cell wall. This disruption leads to loss of cell wall integrity and death of actively replicating Mycobacterium tuberculosis organisms.

The specific dose of Izoniazida Atb is determined by the prescribing clinician based on the patient’s age, weight, disease severity, and treatment guidelines. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety of isoniazid in pregnancy or lactation is assessed case by case. It may be used when the benefit outweighs potential risks, but clinicians usually monitor liver function closely and may supplement with vitamin B6 to reduce neuropathy risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isoniazid is a first‑line agent with high early bactericidal activity, often combined with rifampicin, pyrazinamide and ethambutol. Compared with newer agents, it is inexpensive and well‑studied but carries a higher risk of hepatotoxicity and peripheral neuropathy, requiring monitoring and pyridoxine supplementation.

Store Izoniazida Atb at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Izoniazida Atb is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact administration schedule—once daily or multiple times per day—depends on the prescriber’s regimen and should be followed precisely.

The most serious adverse effects include hepatotoxicity, which can progress to severe hepatitis, and peripheral neuropathy, especially in patients with nutritional deficiencies. Rare but severe skin reactions such as Stevens‑Johnson syndrome may also occur, requiring immediate medical attention.

Patients with known hypersensitivity to isoniazid or any excipients, those with pre‑existing severe liver disease, or individuals who cannot safely receive pyridoxine supplementation should avoid using Izoniazida Atb. Clinicians must evaluate each patient’s medical history before prescribing.